
Kevin T Batty

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9024410/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The effect of sickle cell genotype on the pharmacokinetic properties of artemether-lumefantrine in Tanzanian children. International Journal for Parasitology: Drugs and Drug Resistance, 2022, 19, 31-39.	1.4	0
2	Stability of benzylpenicillin for continuous intravenous infusions: An isotonic formulation for therapeutic use and a low-dose formulation for clinical trial. Journal of Infection and Chemotherapy, 2022, , .	0.8	1
3	Population pharmacokinetic study of benzathine penicillin G administration in Indigenous children and young adults with rheumatic heart disease in the Northern Territory, Australia. Journal of Antimicrobial Chemotherapy, 2022, 77, 2679-2682.	1.3	2
4	High risk of early sub-therapeutic penicillin concentrations after intramuscular benzathine penicillin G injections in Ethiopian children and adults with rheumatic heart disease. PLoS Neglected Tropical Diseases, 2021, 15, e0009399.	1.3	5
5	Stability of pentoxifylline injection: application to neonatal/pediatric care setting. Journal of Pharmaceutical Sciences, 2021, 110, 3862-3865.	1.6	1
6	The Artemiside-Artemisox-Artemisone-M1 Tetrad: Efficacies against Blood Stage P. falciparum Parasites, DMPK Properties, and the Case for Artemiside. Pharmaceutics, 2021, 13, 2066.	2.0	4
7	Ergometrine stability in postpartum haemorrhage kits: Does temperature and light matter?. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2020, 60, 344-349.	0.4	4
8	Subcutaneous administration of benzathine benzylpenicillin G has favourable pharmacokinetic characteristics for the prevention of rheumatic heart disease compared with intramuscular injection: a randomized, crossover, population pharmacokinetic study in healthy adult volunteers. Journal of Antimicrobial Chemotherapy, 2020, 75, 2951-2959.	1.3	14
9	Population Pharmacokinetic Study of Ceftriaxone in Elderly Patients, Using Cystatin C-Based Estimates of Renal Function To Account for Frailty. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	12
10	Quality of benzathine penicillin C: A multinational crossâ€sectional study. Pharmacology Research and Perspectives, 2020, 8, e00668.	1.1	5
11	Compatibility of pentoxifylline and parenteral medications. Archives of Disease in Childhood, 2020, 105, 395-397.	1.0	5
12	A population pharmacokinetic study of benzathine benzylpenicillin G administration in children and adolescents with rheumatic heart disease: new insights for improved secondary prophylaxis strategies. Journal of Antimicrobial Chemotherapy, 2019, 74, 1984-1991.	1.3	16
13	Physical compatibility of pentoxifylline and intravenous medications. Archives of Disease in Childhood, 2019, 104, 292-295.	1.0	6
14	Ertapenem for osteoarticular infections in obese patients: a pharmacokinetic study of plasma and bone concentrations. European Journal of Clinical Pharmacology, 2019, 75, 511-517.	0.8	10
15	Effects of maturation and size on population pharmacokinetics of pentoxifylline and its metabolites in very preterm infants with suspected lateâ€onset sepsis or necrotizing enterocolitis: a pilot study incorporating clinical outcomes. British Journal of Clinical Pharmacology, 2019, 85, 147-159.	1.1	17
16	Validation of a Dried Blood Spot Ceftriaxone Assay in Papua New Guinean Children with Severe Bacterial Infections. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	7
17	Penicillin Dried Blood Spot Assay for Use in Patients Receiving Intramuscular Benzathine Penicillin G and Other Penicillin Preparations To Prevent Rheumatic Fever. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	12
18	Simultaneous determination of pentoxifylline, metabolites M1 (lisofylline), M4 and M5, and caffeine in plasma and dried blood spots for pharmacokinetic studies in preterm infants and neonates. Journal of Pharmaceutical and Biomedical Analysis, 2017, 146, 302-313.	1.4	13

#	Article	IF	CITATIONS
19	Safety, tolerability and pharmacokinetic properties of coadministered azithromycin and piperaquine in pregnant Papua New Guinean women. British Journal of Clinical Pharmacology, 2016, 82, 199-212.	1.1	18
20	Naphthoquine: An Emerging Candidate for Artemisinin Combination Therapy. Drugs, 2016, 76, 789-804.	4.9	16
21	Validation and Application of a Dried Blood Spot Assay for Biofilm-Active Antibiotics Commonly Used for Treatment of Prosthetic Implant Infections. Antimicrobial Agents and Chemotherapy, 2016, 60, 4940-4955.	1.4	10
22	Validation and Application of a Dried Blood Spot Ceftriaxone Assay. Antimicrobial Agents and Chemotherapy, 2016, 60, 14-23.	1.4	28
23	Use of quantitative pharmacology tools to improve malaria treatments. Expert Review of Clinical Pharmacology, 2016, 9, 303-316.	1.3	5
24	Population Pharmacokinetics, Tolerability, and Safety of Dihydroartemisinin-Piperaquine and Sulfadoxine-Pyrimethamine-Piperaquine in Pregnant and Nonpregnant Papua New Guinean Women. Antimicrobial Agents and Chemotherapy, 2015, 59, 4260-4271.	1.4	30
25	Pharmacokinetics of Piperaquine Transfer into the Breast Milk of Melanesian Mothers. Antimicrobial Agents and Chemotherapy, 2015, 59, 4272-4278.	1.4	12
26	Modelling the time course of antimalarial parasite killing: a tour of animal and human models, translation and challenges. British Journal of Clinical Pharmacology, 2015, 79, 97-107.	1.1	13
27	Stabilization of Resveratrol in Blood Circulation by Conjugation to mPEG and mPEG-PLA Polymers: Investigation of Conjugate Linker and Polymer Composition on Stability, Metabolism, Antioxidant Activity and Pharmacokinetic Profile. PLoS ONE, 2015, 10, e0118824.	1.1	22
28	Validation of a chloroquine-induced cell death mechanism for clinical use against malaria. Cell Death and Disease, 2014, 5, e1305-e1305.	2.7	12
29	Interspecies Allometric Scaling of Antimalarial Drugs and Potential Application to Pediatric Dosing. Antimicrobial Agents and Chemotherapy, 2014, 58, 6068-6078.	1.4	7
30	Effect of Coadministered Fat on the Tolerability, Safety, and Pharmacokinetic Properties of Dihydroartemisinin-Piperaquine in Papua New Guinean Children with Uncomplicated Malaria. Antimicrobial Agents and Chemotherapy, 2014, 58, 5784-5794.	1.4	16
31	Pharmacokinetic Properties of Single-Dose Primaquine in Papua New Guinean Children: Feasibility of Abbreviated High-Dose Regimens for Radical Cure of Vivax Malaria. Antimicrobial Agents and Chemotherapy, 2014, 58, 432-439.	1.4	21
32	Predicting the parasite killing effect of artemisinin combination therapy in a murine malaria model. Journal of Antimicrobial Chemotherapy, 2014, 69, 2155-2163.	1.3	18
33	Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis. Nephrology, 2013, 18, 188-193.	0.7	14
34	Mechanism-Based Model of Parasite Growth and Dihydroartemisinin Pharmacodynamics in Murine Malaria. Antimicrobial Agents and Chemotherapy, 2013, 57, 508-516.	1.4	20
35	Artemisinin-Naphthoquine Combination Therapy for Uncomplicated Pediatric Malaria: a Pharmacokinetic Study. Antimicrobial Agents and Chemotherapy, 2012, 56, 2472-2484.	1.4	36
36	Pharmacokinetic Comparison of Two Piperaquine-Containing Artemisinin Combination Therapies in Papua New Guinean Children with Uncomplicated Malaria. Antimicrobial Agents and Chemotherapy, 2012, 56, 3288-3297.	1.4	24

#	Article	IF	CITATIONS
37	Simultaneous determination of primaquine and carboxyprimaquine in plasma using solid phase extraction and LC–MS assay. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 902, 142-146.	1.2	19
38	Chemical Stability of Artesunate Injection and Proposal for its Administration by Intravenous Infusion. Journal of Pharmacy and Pharmacology, 2011, 48, 22-26.	1.2	55
39	A randomised controlled trial of a pharmaceutical care programme in high-risk diabetic patients in an outpatient clinic. International Journal of Pharmacy Practice, 2011, 10, 85-89.	0.3	48
40	Synthesis and antimalarial evaluation of novel isocryptolepine derivatives. Bioorganic and Medicinal Chemistry, 2011, 19, 7519-7525.	1.4	67
41	Improving the solubility and bioavailability of dihydroartemisinin by solid dispersions and inclusion complexes. Archives of Pharmacal Research, 2011, 34, 757-765.	2.7	18
42	Pharmacokinetics, Pharmacodynamics, and Allometric Scaling of Chloroquine in a Murine Malaria Model. Antimicrobial Agents and Chemotherapy, 2011, 55, 3899-3907.	1.4	63
43	Adverse drug reaction reporting in Australian hospitals. International Journal of Pharmacy Practice, 2010, 12, 155-161.	0.3	2
44	Domiciliary medication reviews by fourth year pharmacy students in Western Australia. International Journal of Pharmacy Practice, 2010, 12, 73-81.	0.3	2
45	Investigation of reproductive toxicity of piperaquine in mice. Reproductive Toxicology, 2010, 29, 206-213.	1.3	11
46	Piperaquine Pharmacodynamics and Parasite Viability in a Murine Malaria Model. Antimicrobial Agents and Chemotherapy, 2009, 53, 2707-2713.	1.4	8
47	Toxicology and pharmacokinetics of piperaquine in mice. Toxicology, 2008, 249, 55-61.	2.0	9
48	Plasmodium berghei: Parasite clearance after treatment with dihydroartemisinin in an asplenic murine malaria model. Experimental Parasitology, 2008, 118, 458-467.	0.5	20
49	Pharmacokinetics and Efficacy of Piperaquine and Chloroquine in Melanesian Children with Uncomplicated Malaria. Antimicrobial Agents and Chemotherapy, 2008, 52, 237-243.	1.4	80
50	Pharmacokinetics and Pharmacodynamics of Piperaquine in a Murine Malaria Model. Antimicrobial Agents and Chemotherapy, 2008, 52, 306-311.	1.4	18
51	Pharmacokinetics of Dihydroartemisinin in a Murine Malaria Model. American Journal of Tropical Medicine and Hygiene, 2008, 78, 641-642.	0.6	15
52	Pharmacokinetics of dihydroartemisinin in a murine malaria model. American Journal of Tropical Medicine and Hygiene, 2008, 78, 641-2.	0.6	9
53	Pharmacodynamics of Doxycycline in a Murine Malaria Model. Antimicrobial Agents and Chemotherapy, 2007, 51, 4477-4479.	1.4	12
54	Retinol supplementation in murine Plasmodium berghei malaria: Effects on tissue levels, parasitaemia and lipid peroxidation. International Journal for Parasitology, 2007, 37, 525-537.	1.3	5

#	Article	IF	CITATIONS
55	Development of a pharmacodynamic model of murine malaria and antimalarial treatment with dihydroartemisinin. International Journal for Parasitology, 2007, 37, 1569-1576.	1.3	12
56	In Vitro Interactions between Piperaquine, Dihydroartemisinin, and Other Conventional and Novel Antimalarial Drugs. Antimicrobial Agents and Chemotherapy, 2006, 50, 2883-2885.	1.4	23
57	Role of P Glycoprotein in Absorption of Novel Antimalarial Drugs. Antimicrobial Agents and Chemotherapy, 2006, 50, 3504-3506.	1.4	37
58	Adverse Drug Reaction Reporting: Attitudes of Australian Hospital Pharmacists and Doctors. Journal of Pharmacy Practice and Research, 2005, 35, 9-14.	0.5	6
59	Effect of a Pharmaceutical Care Program on Vascular Risk Factors in Type 2 Diabetes: The Fremantle Diabetes Study. Diabetes Care, 2005, 28, 771-776.	4.3	156
60	Greater use of insulin by southern European compared with Anglo-Celt patients with type 2 diabetes: the Fremantle Diabetes Study. European Journal of Endocrinology, 2004, 151, 579-586.	1.9	8
61	Comparison of gentamicin dose estimates derived from manual calculations, the Australian 'Therapeutic Guidelines: Antibiotic' nomogram and the SeBA-GEN and DoseCalc software programs. British Journal of Clinical Pharmacology, 2004, 58, 521-527.	1.1	23
62	Hepatocellular bioactivation and cytotoxicity of the synthetic endoperoxide antimalarial arteflene. Chemico-Biological Interactions, 2004, 147, 173-184.	1.7	12
63	Protein binding and α : β anomer ratio of dihydroartemisinin in vivo. British Journal of Clinical Pharmacology, 2004, 57, 529-533.	1.1	33
64	Comparison of bioassay and high performance liquid chromatographic assay of artesunate and dihydroartemisinin in plasma. Acta Tropica, 2003, 87, 371-375.	0.9	10
65	Penetration of Dihydroartemisinin into Cerebrospinal Fluid after Administration of Intravenous Artesunate in Severe Falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2003, 47, 368-370.	1.4	51
66	Title is missing!. Pediatric Infectious Disease Journal, 2003, 22, 251-255.	1.1	1
67	Safety and therapeutic efficacy of artesunate suppositories for treatment of malaria in children in Papua New Guinea. Pediatric Infectious Disease Journal, 2003, 22, 251-255.	1.1	23
68	Prevalence and Predictors of Complementary Medicine Usage in Diabetes: Fremantle Diabetes Study. Journal of Pharmacy Practice and Research, 2003, 33, 260-264.	0.5	25
69	Glucuronidation of Dihydroartemisinin in Vivo and by Human Liver Microsomes and Expressed UDP-Glucuronosyltransferases. Drug Metabolism and Disposition, 2002, 30, 1005-1012.	1.7	138
70	The pharmacokinetic properties of intramuscular artesunate and rectal dihydroartemisinin in uncomplicated falciparum malaria. British Journal of Clinical Pharmacology, 2002, 53, 23-30.	1.1	49
71	Relative bioavailability of artesunate and dihydroartemisinin: investigations in the isolated perfused rat liver and in healthy Caucasian volunteers American Journal of Tropical Medicine and Hygiene, 2002, 66, 130-136.	0.6	32
72	Oral bioavailability of dihydroartemisinin in Vietnamese volunteers and in patients with falciparum malaria. British Journal of Clinical Pharmacology, 2001, 51, 541-546.	1.1	68

#	Article	IF	CITATIONS
73	Pharmacokinetics and Pharmacodynamics of Intravenous Artesunate in Severe Falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2001, 45, 181-186.	1.4	90
74	Assessment of the effect of malaria infection on hepatic clearance of dihydroartemisinin using rat liver perfusions and microsomes. British Journal of Pharmacology, 1998, 125, 159-167.	2.7	22
75	A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. British Journal of Clinical Pharmacology, 1998, 45, 123-129.	1.1	105
76	The pharmacokinetics of artemisinin (ART) and artesunate (ARTS) in healthy volunteers American Journal of Tropical Medicine and Hygiene, 1998, 58, 125-126.	0.6	6
77	A pharmacokinetic and pharmacodynamic study of artesunate for vivax malaria American Journal of Tropical Medicine and Hygiene, 1998, 59, 823-827.	0.6	55
78	Severe falciparum malaria with hyperparasitaemia treated with intravenous artesunate. Medical Journal of Australia, 1997, 166, 416-418.	0.8	15
79	Selective high-performance liquid chromatographic determination of artesunate and α- and β-dihydroartemisinin in patients with falciparum malaria. Biomedical Applications, 1996, 677, 345-350.	1.7	112
80	Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial. British Journal of Clinical Pharmacology, 1996, 42, 415-421.	1.1	44
81	The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects British Journal of Clinical Pharmacology, 1995, 39, 305-311.	1.1	59
82	Asthma knowledge in hospital patients with acute severe asthma. Medical Journal of Australia, 1994, 160, 609-610.	0.8	4
83	NSAID prescribing information. Australian and New Zealand Journal of Medicine, 1992, 22, 386-386.	0.5	0
84	Evaluation of Generic-Brand Name Knowledge. DICP: the Annals of Pharmacotherapy, 1991, 25, 1138-1138.	0.2	1
85	Effect of Urine pH on the Stability of Doxorubicin and its Recovery from Bladder Instillations. British Journal of Urology, 1990, 65, 478-482.	0.1	3
86	Hypersensitivity to methylhydroxyâ€benzoate: a case for additive labelling of pharmaceuticals. Medical Journal of Australia, 1986, 144, 107-107.	0.8	4
87	Cytotoxic-spill kit and spill-control procedure. American Journal of Health-System Pharmacy, 1986, 43, 2235-2236.	0.5	1
88	Piperaquine Pharmacokinetic and Pharmacodynamic Profiles in Healthy Volunteers of Papua New Guinea after Administration of Three-Monthly Doses of Dihydroartemisinin–Piperaquine. Antimicrobial Agents and Chemotherapy, 0, , .	1.4	0